Yahoo
ASX - Delayed Quote AUD

Actinogen Medical Limited (ACW.AX)

0.0420 -0.0010 (-2.33%)
At close: October 30 at 4:10:11 PM GMT+11
Chart Range Bar
Loading chart for ACW.AX
  • Previous Close 0.0430
  • Open 0.0430
  • Bid 0.0410 x --
  • Ask 0.0420 x --
  • Day's Range 0.0400 - 0.0450
  • 52 Week Range 0.0310 - 0.0720
  • Volume 5,311,121
  • Avg. Volume 4,661,260
  • Market Cap (intraday) 162.715M
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 0.08

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

actinogen.com.au

--

Full Time Employees

June 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

ACW.AX
31.15%
S&P/ASX 200 [XJO] (^AXJO)
2.22%

1-Year Return

ACW.AX
20.00%
S&P/ASX 200 [XJO] (^AXJO)
0.29%

3-Year Return

ACW.AX
147.06%
S&P/ASX 200 [XJO] (^AXJO)
31.37%

5-Year Return

ACW.AX
69.84%
S&P/ASX 200 [XJO] (^AXJO)
21.63%

Analyst Insights

View More

Analyst Price Targets

0.08
0.08 Average
0.0420 Current
0.08 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -121.35%

  • Return on Assets (ttm)

    -35.71%

  • Return on Equity (ttm)

    -77.46%

  • Revenue (ttm)

    12.67M

  • Net Income Avi to Common (ttm)

    -15.38M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.73M

  • Total Debt/Equity (mrq)

    22.38%

  • Levered Free Cash Flow (ttm)

    -12.54M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: